India, May 30 -- Investment firm Carlyle Group Inc. (CG), along with SK Capital Partners, LP and Beacon Parent Holdings, L.P., on Friday announced that the proposed acquisition of bluebird bio, Inc. (BLUE) would close on June 2 as all conditions of the tender offer have been met.
The tender offer, which was launched on March 7 to acquire bluebird bio, expired on May 29, and was not extended.
It was in mid February that Bluebird Bio agreed to be acquired by Carlyle And SK Capital for either $3.00 per share plus a potential $6.84 in cash per contingent value right per share, or $5.00 per share in cash.
Equiniti Trust Company reported that about 5.87 million shares, or 59.8% of bluebird's outstanding stock, were validly tendered by the dead...